CLARITHROMYCIN 500mg. IP

A semisynthetic macrolide antibiotic displays a broad-spectrum activity against gram-positive, gram-negative, and atypical respiratory tract and skin/skin structure pathogens, Mycobacterium species, and Helicobacter pylori. (D R Guay, 2001) A promising alternative to other macrolides in the treatment of community-acquired infections. (F Fraschini, 1993) Has a potential advantage over erythromycin as it is more active against Staphylococcus aureus, streptococci, Legionella pneumophila, Moraxella catarrhalis. (S C Piscitelli, 1992) An effective candidate for the treatment of upper-respiratory tract and lower-respiratory tract infections and infections of the skin and skin structures. (S C Piscitelli L. H., 1992) Possesses better tolerability than erythromycin, penicillin VK, ampicillin, or amoxicillin for treatment of a variety of upper and lower respiratory tract or skin infections. (Sturgill MG, 1992)